Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Teva Pharmaceutical Industries Limited (TEVA)

8.44   -0.09 (-1.06%) 03-24 16:00
Open: 8.42 Pre. Close: 8.53
High: 8.535 Low: 8.28
Volume: 7,776,217 Market Cap: 9,375(M)

Technical analysis

as of: 2023-03-24 4:30:27 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 11     One year: 11.84
Support: Support1: 8.27    Support2: 6.88
Resistance: Resistance1: 9.42    Resistance2: 10.14
Pivot: 8.92
Moving Average: MA(5): 8.6     MA(20): 9.18
MA(100): 9.51     MA(250): 9.03
MACD: MACD(12,26): -0.5     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 15.8     %D(3): 20.1
RSI: RSI(14): 31.2
52-week: High: 11.44  Low: 6.78
Average Vol(K): 3-Month: 9,094 (K)  10-Days: 11,021 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ TEVA ] has closed above bottom band by 23.5%. Bollinger Bands are 29.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 8.55 - 8.6 8.6 - 8.64
Low: 8.16 - 8.23 8.23 - 8.28
Close: 8.35 - 8.45 8.45 - 8.53

Company Description

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Headline News

Sat, 25 Mar 2023
Teva Pharmaceutical Industries Limited is acquired by Assenagon ... - Best Stocks

Sat, 25 Mar 2023
DNB Asset Management AS Sells 8900 Shares of Teva ... - Defense World

Fri, 24 Mar 2023
Teva Pharmaceutical Industries Limited (TEVA) Stock Sees a-2.29 ... - The News Heater

Thu, 23 Mar 2023
Teva Pharmaceutical Industries Enters Oversold Territory (TEVA) - Nasdaq

Tue, 21 Mar 2023
Where Does Wall Street Think Teva Pharmaceutical Industries Ltd (TEVA) Stock Will Go? - InvestorsObserver

Mon, 20 Mar 2023
Baker McKenzie advises on USD 2.5 billion (equivalent ... - Baker McKenzie

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 1,110 (M)
Shares Float 1,100 (M)
% Held by Insiders 2 (%)
% Held by Institutions 49.6 (%)
Shares Short 25,570 (K)
Shares Short P.Month 28,350 (K)

Stock Financials

EPS -2
EPS Est Next Qtl 1.09
EPS Est This Year 4.23
EPS Est Next Year 3.69
Book Value (p.s.) 7.11
Profit Margin (%) -15.8
Operating Margin (%) 17.8
Return on Assets (ttm) 3.6
Return on Equity (ttm) -24.2
Qtrly Rev. Growth -5.4
Gross Profit (p.s.) 6.27
Sales Per Share 13.44
EBITDA (p.s.) 3.57
Qtrly Earnings Growth 0
Operating Cash Flow 1,590 (M)
Levered Free Cash Flow 2,900 (M)

Stock Valuations

PE Ratio -4.25
PEG Ratio 0.9
Price to Book value 1.18
Price to Sales 0.62
Price to Cash Flow 5.89

Stock Dividends

Dividend 0.09
Forward Dividend 0
Dividend Yield 1%
Dividend Pay Date 2017-12-11
Ex-Dividend Date 2017-11-26
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.